Phentermine is a sympathomimetic appetite suppressant that stimulates noradrenaline release in the brain, reducing hunger. It is FDA-approved only for short-term use (a few weeks) as an adjunct to diet and activity. It suppresses appetite modestly, carries cardiovascular cautions, and is not intended as long-term therapy on its own.
Obesity Medication Library entry. Section accent: family --teal.
DRUG FACT PANEL
| Generic | Phentermine |
| Brands | Adipex-P, Lomaira (also a component of Qsymia — see phentermine/topiramate) |
| Class | Sympathomimetic amine (appetite suppressant); a controlled substance |
| Mechanism (1 line) | Stimulates release of noradrenaline centrally, suppressing appetite |
| FDA indication | Short-term (a few weeks) adjunct for weight reduction in obesity |
| Who it's for | Adults needing short-term appetite suppression, without cardiovascular contraindications |
| Route/formulation | Oral, once daily (various strengths) |
| Titration concept | Lowest effective dose; time-limited course — individual dosing is set by a clinician, not this page |
| Expected effect | Modest short-term weight loss — on the order of ~5% of body weight over a few weeks to months in short-term monotherapy trials (added to diet/activity); not studied for durable long-term loss as monotherapy, and below the GLP-1/dual-agonist agents |
| Evidence level (obesity) | Grade B 🟡 for short-term use; long-term monotherapy evidence limited |
What phentermine is
Phentermine is one of the oldest weight-loss drugs still in use, approved in the United States since 1959. It is a sympathomimetic amine — chemically related to amphetamine but with far weaker central-stimulant and abuse potential — and is a scheduled controlled substance. It is approved for short-term use only, a legacy of how obesity drugs were studied decades ago, and it is also one half of the modern combination Qsymia (phentermine/topiramate), where it is used at lower doses for chronic management. → Phentermine/Topiramate
How it works
Phentermine acts centrally to stimulate the release of noradrenaline (and, to a lesser degree, other catecholamines), which suppresses appetite. Reduced hunger makes it easier to eat less, but the drug does not target the deeper appetite-regulating incretin biology that the GLP-1 agents engage — which is part of why its effect is more modest and less durable. → Why Weight Is So Hard to Lose
What the trials actually show
Phentermine's approval rests on older, short-term studies showing modest weight loss versus placebo over a few weeks. It has not been studied as long-term monotherapy to the standard now expected of newer obesity drugs; the strong long-term evidence for a phentermine-containing regimen comes from the combination with topiramate (Qsymia). Its standalone effect is best described as modest and short-term — roughly ~5% of body weight over a few weeks to months versus placebo, added to diet and activity — well below what the GLP-1 and dual-agonist drugs achieve, and it lacks the durable long-term evidence they carry. → Phentermine/Topiramate
Side effects
Common: increased heart rate, palpitations, elevated blood pressure, insomnia, dry mouth, restlessness, jitteriness, constipation, headache. Many reflect its stimulant-like action.
Less common / serious: meaningful blood-pressure elevation, arrhythmia, and — the historically important concern — the drug's stimulant profile is why cardiovascular screening matters before use. (Note: the 1990s valvular-disease scare involved fen-phen, the combination with fenfluramine; fenfluramine was withdrawn. Phentermine itself was not the withdrawn agent, but the episode shaped its cautious, short-term positioning.)
Contraindications & cautions
- Cardiovascular disease — coronary disease, arrhythmias, heart failure, uncontrolled hypertension, stroke history.
- Hyperthyroidism.
- Glaucoma.
- History of substance use / agitation — given its stimulant class and controlled status.
- Concurrent or recent MAO inhibitors — risk of hypertensive crisis.
- Pregnancy and breastfeeding — not recommended (see below).
Monitoring, pregnancy and surgery
- Monitoring: blood pressure and heart rate before and during treatment; sleep and mood; response. Cardiovascular status should be reassessed, not assumed.
- Pregnancy/lactation: not recommended in pregnancy; weight loss is not a goal during pregnancy. Discontinue if pregnancy is planned or confirmed. → Women's Health & Obesity
- Perioperative: discuss sympathomimetic use with the anaesthesia team, given cardiovascular and blood-pressure effects.
Long-term considerations, discontinuation and weight regain
Because phentermine is approved for short-term use, it is not a maintenance strategy on its own; the underlying appetite biology returns when it is stopped, and weight regain is expected without a longer-term plan. This limitation is precisely why it is combined with topiramate in Qsymia for chronic management, and why many patients who need durable pharmacotherapy are better served by agents studied for long-term use. Discontinuation is generally straightforward, though some rebound in appetite can occur. → Weight Regain & Maintenance
Unanswered questions
- Its optimal role now that incretin therapies dominate long-term treatment.
- Long-term cardiovascular safety of intermittent or repeated short courses.
- How best to bridge from short-term phentermine to durable maintenance.
Questions patients ask
How does phentermine work?
It's a sympathomimetic — it stimulates noradrenaline release in the brain, which suppresses appetite so you eat less. It doesn't engage the incretin appetite biology that GLP-1 drugs do. Grade B 🟡
Why is it only approved for a few weeks?
Its approval rests on older short-term studies, and its stimulant profile carries cardiovascular cautions. Long-term monotherapy hasn't been established to modern standards. Grade B 🟡
Is phentermine dangerous for the heart?
It can raise heart rate and blood pressure, so it's cautioned or contraindicated in cardiovascular disease and uncontrolled hypertension. Screening and monitoring matter. Grade B 🟡 → Obesity & Cardiovascular Health
Wasn't phentermine the drug that damaged heart valves?
No — that was fen-phen, the combination with fenfluramine, which was withdrawn. Phentermine alone wasn't the withdrawn agent, but the episode is why it's used cautiously. Grade A 🟢
Will I regain weight after stopping?
Usually yes, because it's short-term and doesn't change the underlying appetite biology. A longer-term plan is needed for durable results. Grade A 🟢 → Weight Regain & Maintenance
Is it the same as the phentermine in Qsymia?
Yes — Qsymia pairs lower-dose phentermine with topiramate for chronic use, which is studied for longer-term weight management. Grade A 🟢 → Phentermine/Topiramate
KEEP READING
- Obesity Medication Library — where phentermine sits among all approved options.
- Phentermine/Topiramate (Qsymia) — the combination studied for long-term use.
- Obesity & Cardiovascular Health — why cardiovascular screening matters here.
- Weight Regain & Maintenance — why short-term drugs alone don't hold weight off.
Written by Darius A. Schneider, MD, PhD · Board-Certified Endocrinologist (ECNU) · Last updated: 2026-08-10 · References: Phentermine FDA prescribing information; historical fen-phen safety record; obesity pharmacotherapy guidelines. Not individualized medical advice.
